NR AOZF
AU Sitzmann,L.; Brandel,J.P.; Delasnerie-Laupretre,N.; Laplanche,J.L.; Perret-Liaudet,A.; Fleury,H.; Alperovitch,A.
TI Could a Modification of Inclusion Criteria Lead to an Earlier Treatment of Patients With Sporadic CJD ?
QU International Conference - Prion diseases: from basic research to intervention concepts - TSE-Forum, 08.10.-10.10.2003, Gasteig, München - Poster session - DG-49
PT Konferenz-Poster
AB It is well known that drugs used in animal models diseases are effective if they are administrated during incubation time or at the beginning of the clinical period.Lack of demonstrated efficiency of drugs in Creutzfeldt-Jakob Disease (CJD) could be a consequence of a delayed treatment. At present, most of the patients are treated when they fulfil clinical criteria of probable CJD, corresponding to a relatively advanced stage of the disease. The aim of this study was to try to define criteria for an early inclusion of CJD patients in clinical trials.In France, most of the patients are notified to surveillance network at the time of lumbar puncture for 14-3-3 detection. We have analysed clinical features of 291 patients with a final diagnosis of probable or definite sporadic CJD with a complete neurological evaluation at the time of the lumbar puncture.Clinical data at the time of the lumbar puncture and 14-3-3 test reuslts allowed to classify 244 out of 291 (84%) cases as probable CJD. Mean durations between onset of the disease and lumbar puncture and between puncture and death were respectively of 3.7 and 1.7 months. Modification of inclusion criteria would allow to include in therapeutic procedure only 15% of further patients with a decrease on diagnosis reliability. The inclusion of patients at a rather advanced stage is due to the sub-acute course of the disease. The short interval between lumbar puncture and death stresses the difficulties to conduct therapeutic studies on sporadic CJD.
AD L. Sitzmann, J.P. Brandel, Cellule Nationale de Référence de la MCJ, Hôpital Pitié-Salpétrière Paris France; N. Delasnerie Lauprêtre, A. Alpérovitch, Inserm U360, Hôpital Pitié-Salpétrière Paris France; J.L. Laplanche, A. Perret-Liaudet, Service de biochimieet biologie moléculaire, Hôpital Lariboisière Paris France; H. Fleury, Laboratoire de virologiesystématique et moléculaire USB Hôpital Pellegrin, Bordeaux France
SP englisch
PO Deutschland